Skip to main content
DRIO
NASDAQ Industrial Applications And Services

DarioHealth Q3 Loss Narrows to $8.8M; Covenant Cured With $22.8M of Offering Proceeds

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.125
Mkt Cap
$20.824M
52W Low
$1.695
52W High
$14.77
52W Position info
25% above low
Off High info
86% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

DRIO sits 25% above its 52-week low of $1.695 on elevated volume (1.9× avg).

Summary

DarioHealth reported a $8.8M Q3 loss versus $10.5M a year ago and $27.8M of cash, but disclosed it breached its Callodine EBITDA covenant at quarter-end and cured it with $22.8M of July offering proceeds — its first and only equity cure.


Key Events · Earnings and Guidance · DRIO

  • Q3 Loss Narrows, Revenue Up 6%

    Net loss was $8.849M versus $10.466M a year earlier; Q3 revenue rose 6.1% to $5.311M, though nine-month revenue fell 6.2% to $16.071M.

  • Covenant Breach Cured With Offering Cash

    The company did not satisfy the Callodine EBITDA covenant at September 30, 2026 and designated $22.824M of July 2026 offering proceeds as its first Equity Cure; no Event of Default exists, but that cure right is now consumed.

  • Cash Position and Burn

    Cash and equivalents were $27.844M plus $3.309M of short-term deposits at September 30, 2026, against $17.646M of nine-month operating cash use — roughly a year of runway at the current pace.

  • Warrant Overhang Remains Large

    3,271,021 pre-funded warrants were exercisable into common stock at September 30, 2026, versus 11,197,024 shares outstanding; 90,000 were exercised in October, leaving 3,181,021.


Analysis · DRIO · Industrial Applications And Services

The headline here is the balance sheet, not the smaller loss: DarioHealth missed the EBITDA covenant on its Callodine term loan at September 30 and stayed in compliance only by designating $22.8M of its July equity raise as an equity cure. That cure right is now used up, leaving the next covenant test with no cushion from this financing. Cash of $27.8M plus $3.3M in deposits against $17.6M of nine-month operating burn leaves roughly a year of runway at the current pace, and revenue is still shrinking year over year.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DRIO was trading at $2.13 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $1.70 to $14.77. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DRIO - Latest Insights

DRIO
Nov 12, 2026, 6:36 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.13
Real-time Price: $1.67 info
Change: -$0.460 (-22%) info
Market Cap: $16.316M info
DRIO
Sep 17, 2026, 7:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $6.78
Real-time Price: $1.67 info
Change: -$5.12 (-75%) info
Market Cap: $16.316M info
DRIO
Aug 11, 2026, 6:38 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $7.66
Real-time Price: $1.67 info
Change: -$6.00 (-78%) info
Market Cap: $16.316M info
DRIO
Aug 11, 2026, 6:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.66
Real-time Price: $1.67 info
Change: -$6.00 (-78%) info
Market Cap: $16.316M info
DRIO
Jul 22, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $7.99
Real-time Price: $1.67 info
Change: -$6.33 (-79%) info
Market Cap: $16.316M info